Table 4.

Quantitative results of TST, C-TST and IGRA at the baseline and 3-month follow-up survey.

Subgroup	TST induration mm,median (IQR)				C-TST induration/ erythema mm, median (IQR)				IGRA
									TB1-Nil IU/ml, median (IQR)				TB2-Nil IU/ml, median (IQR)
	N	Baseline	3-month follow-up	P	N	Baseline	3-month follow-up	P	N	Baseline	3-month follow-up	P	Baseline	3-month follow-up	P
Baseline -/follow-up +	50	0.00 (0.00-0.00)	13.50 (11.50-17.00)	< 0.001	26	0.00 (0.00-0.00)	20.00 (17.00-24.00)	< 0.001	27	0.13 (0.03-0.23)	0.50 (0.29-1.41)	< 0.001	0.16 (0.05-0.24)	0.62 (0.36-1.47)	< 0.001
Baseline +/follow-up +	35	15.00 (11.50-19.50)	17.00 (16.00-20.00)	0.043	38	18.00 (14.00-23.50)	24.00 (20.00-31.00)	< 0.001	52	1.24 (0.60-2.68)	2.10 (1.15-4.12)	< 0.001	1.12 (0.64-2.78)	2.33 (1.14-3.80)	< 0.001

C-TST, Creation tuberculin skin test; IGRA, Interferon-gamma release assay; IQR, Interquartile range; TST, Tuberculin skin test; The differences were tested by Wilcoxon matched-pairs signed-rank test.